Treatment with second line antirheumatic drugs often produces side effects. In this report we describe an exceptional patient with rheumatoid arthritis who developed isolated thrombocytopenia during successive treatments with aurothioglucose, sulphasalazine, and hydroxychloroquine. Although thrombocytopenia is a common side effect of parenteral gold, it is very rare during treatment with sulphasalazine and has only once been reported to be caused by hydroxychloroquine.
Case report A 56 year old woman had had seropositive rheumatoid arthritis since January 1986. Initial treatment consisted of non-steroidal antiinflammatory drugs. Because of persistent disease activity, parenteral gold (aurothioglucose 50 mg weekly) was added. After five months this effective treatment had to be discontinued because ofdermatitis and proteinuria. Parenteral gold treatment was reinstated after one year in a very low dose (5 mg monthly). During the four months that this low dose treatment was given, the patient reported neither improvement nor side effects.
In August 1988 the patient visited our hospital for the first time. Physical examination showed active polyarthritis of the hands, wrists, elbows, and forefeet. Laboratory investigations showed an increased erythrocyte sedimentation rate (ESR) 
